<DOC>
	<DOC>NCT01855360</DOC>
	<brief_summary>The objective of the study is to determine whether the combination of the bile acid TUDCA, and doxycycline will slow the progression of familial and senile amyloidosis.</brief_summary>
	<brief_title>Tolerability and Efficacy of a Combination of Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Tauroursodeoxycholic acid</mesh_term>
	<mesh_term>Taurochenodeoxycholic Acid</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Documented transthyretin cardiac amyloidosis by biopsy and staining using immunohistochemistry or mass spectrometry Echocardiographic appearance of left ventricular wall thickness of 13mm or more in the absence of hypertensive heart disease Confirmed ATTR or SSA by genetic testing Age 1890 Male or nonpregnant, nonlactating females Willingness to return to the treatment center for followup Prior liver transplantation or liver transplantation anticipated in less than 6 months Alanine Transaminase and/or Aspartate Transaminase ≥2 x upper normal limit (UNL) Alkaline Phosphatase ≥2 x UNL Creatinine clearance &lt;20 mL/min Any other lab values that in the opinion of the investigator might place the subject at unacceptable risk for participation in the study History of poor compliance History of hypersensitivity to any of the ingredients of the study therapies Any investigational drug within 4 weeks prior to study entry or during the study Current use of diflunisal for therapy of amyloidosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>amyloid</keyword>
	<keyword>amyloidosis</keyword>
	<keyword>cardiac amyloidosis</keyword>
	<keyword>senile amyloidosis</keyword>
	<keyword>familial amyloidosis</keyword>
	<keyword>transthyretin amyloidosis</keyword>
</DOC>